Pieris was founded in 2001 based on the groundbreaking discovery of Anticalin proteins and their potential as therapeutics, which was made at the Technical University of Munich. The company’s goal has always been to commercialize this technology both through partnerships with pharmaceutical and biotech companies as well as through development of proprietary drugs.

The company has been financed by leading biotechnology-focused venture capital firms since 2002  including OrbiMed Advisors, Forbion Capital, Gilde Healthcare Partners, Novo Nordisk Ventures, Global Life Science Ventures, BayTech Venture Capital, Bio-M, TCB, KfW and BayernKapital.

In addition to venture financing, Pieris has secured funding through multiple partnerships, including collaborations with Daiichi Sankyo Company Limited, Sanofi, Sanofi Pasteur and Allergan, Inc. Both on its own and together with its partners, Pieris is developing multiple Anticalin therapeutic programs. In 2010, Pieris conducted the first clinical study of an Anticalin in Oncology patients. A further clinical trial in healthy volunteers with another Anticalin to treat anemia was initiated in December 2014. Furthermore, several partnered Anticalin programs are advancing towards and in the clinic, including Daiichi Sankyo's partnered Anticalin protein against PCSK9, where a Phase I clinical study was initiated in November 2015.

On December 18, 2014, Pieris became a publicly traded company (NASDAQ: PIRS).